On Friday, Shares of Prima Biomed Ltd. (NASDAQ:PBMD), gained 1.57% to $1.29.
Prima Biomed Ltd., declared that it has received positive Scientific Advice from the European Medicines Agency on the development path for its lead product, IMP321 in metastatic breast cancer.
The EMA, located in London, is the agency responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. After dialogue between Prima and the EMA, the Agency has now confirmed in writing its endorsement of the development program of IMP321 in metastatic breast cancer.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product presently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.
Shares of Jarden Corp (NYSE:JAH), inclined 1.36% to $ 52.31, during its last trading session.
Jarden Corporation, declared that the Company will release its financial results for the second quarter 2015 before the markets open on Wednesday, July 29, 2015.
Jarden will host a webcast/dial-in conference call to talk about its financial results at 8:30 a.m. Eastern Time on Wednesday, July 29, 2015. Participants on the call will comprise Martin E. Franklin, Founder and Executive Chairman; James E. Lillie, Chief Executive Officer; and Alan W. LeFevre, Chief Financial Officer.
Jarden Corporation manufactures, markets, and distributes consumer products worldwide. The company’s Outdoor Solutions segment offers camping and outdoor equipment; fishing and team sports equipment; alpine and nordic skiing, snowboarding, snowshoeing, and in-line skating products; technical and outdoor apparel and equipment; personal flotation devices, water sports equipment, and all-terrain vehicle gears; and inflatable air beds and accessories.
At the end of Friday’s trade, Shares of AstraZeneca plc (ADR) (NYSE:AZN), gained 66.45% to $2.94.
AstraZeneca, declared its ongoing support for patients through our longstanding patient assistance programs. In 2014 alone, the AZ&Me Prescription Savings Programs offered more than $670 million in savings to nearly 383,000 patients in the United States.
“As seen with the recent Supreme Court ruling to uphold healthcare subsidies, the discussions around healthcare in the United States continue to evolve. We remain committed to offering our patient assistance programs as this dialogue progresses,” said Diane Sullivan, Vice President, Market Access & Patient Strategies. “We believe it’s not enough for us to simply make great medicines. We have to assist ensure that the people who need those medicines have access to them.”
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide.
Finally, TASER International, Inc. (NASDAQ:TASR), ended its last trade with 1.98% gain, and closed at $33.04.
TASER International, declared Evidence.com for prosecutors, a new platform that enables prosecutors to manage any type of digital evidence shared from their law enforcement partners for free on a Standard License. The First Circuit of Florida State Attorney’s Office has signed a five year contract for 250 prosecutor licenses, which will allow them to better manage the tidal wave of digital evidence that is being generated from police body cameras and other digital devices.
Through early trials, more than 7 terabytes of data from more than 8,000 cases have been shared between prosecutors and local police agencies on the Evidence.com platform. With the Standard Prosecutor License prosecutors receive free unlimited data storage for all evidence shared with them, which allows jurisdictions to experience the full benefits of body-worn video while minimizing the technical challenges posed by new forms of evidence. In addition to receiving digital evidence from law enforcement, prosecutors will be able to electronically provide discovery and enact their own retention policies and audit controls. Accessible for $39 per user per month, prosecutors can purchase a Pro License, which unlocks premium features like redaction, advanced reporting, and other enterprise features.
TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs) worldwide. It operates through two segments, TASER Weapons and AXON. The company’s CEW products transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
